コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and therapy for several malignancies (e.g., pancreatic adenocarcinomas).
2 limited the use of P-AR for locally advanced pancreatic adenocarcinoma.
3 an 65 years and an overall increased risk of pancreatic adenocarcinoma.
4 HDAC-1, -2, -4 and -6 protein expression in pancreatic adenocarcinoma.
5 mily members with possible predisposition to pancreatic adenocarcinoma.
6 rognostic accuracy in LN-positive resectable pancreatic adenocarcinoma.
7 e/boost vaccination with GVAX and CRS-207 in pancreatic adenocarcinoma.
8 reoperative SCPN in patients with resectable pancreatic adenocarcinoma.
9 des a representative preclinical platform in pancreatic adenocarcinoma.
10 and (2) positively with improved survival in pancreatic adenocarcinoma.
11 endent prognostic factor after resection for pancreatic adenocarcinoma.
12 eutic targets for both familial and sporadic pancreatic adenocarcinoma.
13 developing human liver and pancreas, and in pancreatic adenocarcinoma.
14 ding a genetically engineered mouse model of pancreatic adenocarcinoma.
15 patients with locally advanced unresectable pancreatic adenocarcinoma.
16 of clear cell renal cell carcinoma (RCC) and pancreatic adenocarcinoma.
17 ses with ongoing sequencing efforts in human pancreatic adenocarcinoma.
18 ncreatic juice of a patient suffering from a pancreatic adenocarcinoma.
19 of surgical intervention for screen-detected pancreatic adenocarcinoma.
20 ment approaches are needed for patients with pancreatic adenocarcinoma.
21 e treatment of notoriously therapy-resistant pancreatic adenocarcinoma.
22 th patients resected for conventional ductal pancreatic adenocarcinoma.
23 ouse model of pancreatic cancer and in human pancreatic adenocarcinoma.
24 opulations arising in primary and metastatic pancreatic adenocarcinoma.
25 erapy administered in patients with resected pancreatic adenocarcinoma.
26 fectiveness of treatment for screen-detected pancreatic adenocarcinoma.
27 of matched patients with conventional ductal pancreatic adenocarcinoma.
28 for many diseases of the pancreas, including pancreatic adenocarcinoma.
29 th borderline resectable or locally advanced pancreatic adenocarcinoma.
30 cell lung cancer, head and neck cancer, and pancreatic adenocarcinoma.
31 pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma.
32 ronic pancreatitis and its relationship with pancreatic adenocarcinoma.
33 odenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma.
34 use of morbidity and a known risk factor for pancreatic adenocarcinoma.
35 rrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma.
36 s an important tumor marker in patients with pancreatic adenocarcinoma.
37 es with Nox4 both in PaCa cells and in human pancreatic adenocarcinoma.
38 s performed on 360 consecutive patients with pancreatic adenocarcinoma.
39 endoscopy in the diagnosis and treatment of pancreatic adenocarcinoma.
40 that influence the metastatic properties of pancreatic adenocarcinoma.
41 a signaling may promote tumor progression in pancreatic adenocarcinoma.
42 eritumoral SPARC expression in patients with pancreatic adenocarcinoma.
43 cisplatin for patients with locally advanced pancreatic adenocarcinoma.
44 in a range of human malignancies, including pancreatic adenocarcinoma.
45 te to the early spread and poor prognosis of pancreatic adenocarcinoma.
46 nt prognostic factors stratify patients with pancreatic adenocarcinoma.
47 s well as a potential therapeutic target, in pancreatic adenocarcinoma.
48 e abdominal pain resulting from unresectable pancreatic adenocarcinoma.
49 at plays an important role in the biology of pancreatic adenocarcinoma.
50 CEACAM6 is a novel biomarker for pancreatic adenocarcinoma.
51 SCO's recommendations on potentially curable pancreatic adenocarcinoma.
52 pathologic features and clinical outcome in pancreatic adenocarcinoma.
53 be a target for therapeutic intervention in pancreatic adenocarcinoma.
54 eatment and palliation of complications from pancreatic adenocarcinoma.
55 can be detected in the sera of patients with pancreatic adenocarcinoma.
56 ls for those at increased risk of developing pancreatic adenocarcinoma.
57 to be associated with an increased risk for pancreatic adenocarcinoma.
58 chronic pancreatitis, diabetes mellitus, and pancreatic adenocarcinoma.
59 attern of chronic pancreatitis, diabetes and pancreatic adenocarcinoma.
60 lic reprogramming is an emerging hallmark of pancreatic adenocarcinoma.
61 adjuvant therapy-for early-stage resectable pancreatic adenocarcinoma.
62 for patients who had undergone resection for pancreatic adenocarcinoma.
63 ation and assessment of cystic precursors to pancreatic adenocarcinoma.
64 ether have value for classifying subtypes of pancreatic adenocarcinoma.
65 reproducibility of previous AJCC staging for pancreatic adenocarcinoma.
66 Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma.
67 ection tool, in the management of resectable pancreatic adenocarcinoma.
68 evant to the pathologies of pancreatitis and pancreatic adenocarcinoma.
69 involvement is a major prognostic factor in pancreatic adenocarcinoma.
70 significantly higher than reported for human pancreatic adenocarcinomas.
71 or overexpressed in gastric, esophageal and pancreatic adenocarcinomas.
72 c Kras allele, we observed highly metastatic pancreatic adenocarcinomas.
73 ived from the staging algorithm for exocrine pancreatic adenocarcinomas.
74 in pancreatic tumor xenografts and clinical pancreatic adenocarcinomas.
75 enetic step in the development and growth of pancreatic adenocarcinomas.
76 rosine kinase Src is overexpressed in 70% of pancreatic adenocarcinomas.
77 have been identified in approximately 50% of pancreatic adenocarcinomas.
78 feature common to the vast majority of human pancreatic adenocarcinomas.
79 s been shown in many human tumors, including pancreatic adenocarcinomas.
80 ranscriptionally unrepresentative of primary pancreatic adenocarcinomas.
81 ce of MUC4, an aberrantly expressed mucin in pancreatic adenocarcinomas.
82 the pathogenesis of cancers such as lung and pancreatic adenocarcinomas.
83 Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general re
84 adenocarcinomas, 144 patients with familial pancreatic adenocarcinoma, 115 spouses of patients with
85 studied 250 patients with resected sporadic pancreatic adenocarcinomas, 144 patients with familial p
86 ovided the greatest benefit to patients with pancreatic adenocarcinoma: 2.31% of these patients who r
90 ndividuals at high-risk (HRIs) of developing pancreatic adenocarcinoma allows for identification and
92 lastic epithelium of 90% (43 of 48) of human pancreatic adenocarcinomas analyzed by immunohistochemis
94 S: A case-control study of 841 patients with pancreatic adenocarcinoma and 754 healthy individuals fr
96 for the treatment of advanced or metastatic pancreatic adenocarcinoma and advanced epithelial ovaria
97 18)F-FTT uptake was seen in one subject with pancreatic adenocarcinoma and another with liver cancer.
98 npatient, or emergency department), dates of pancreatic adenocarcinoma and death, and modified Charls
99 d on cell lines derived from lung cancer and pancreatic adenocarcinoma and found a correlation betwee
100 s model to predict survival of patients with pancreatic adenocarcinoma and generated a decision model
102 Cox hazard models were constructed; incident pancreatic adenocarcinoma and mortality were outcome eve
103 ients with complete gross total resection of pancreatic adenocarcinoma and no prior radiation or chem
104 d a major role in regulating the survival of pancreatic adenocarcinoma and small-cell lung cancer-der
105 emcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and sa
106 GF-axis genes in 333 patients with localized pancreatic adenocarcinoma and validated the findings in
107 nomic profiles of clonal populations from 40 pancreatic adenocarcinomas and a set of prostate adenoca
108 inase Mirk is overexpressed in many resected pancreatic adenocarcinomas and is amplified in a subset
109 tly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role i
110 actor (CTGF) expression is elevated in human pancreatic adenocarcinomas and some pancreatic cancer ce
111 carcinoma), CFPAC-1 (human metastatic ductal pancreatic adenocarcinoma), and HPAF-II cells (human pan
112 these drugs, others such as prostate cancer, pancreatic adenocarcinoma, and melanoma are resistant.
114 pression has been reported in 53%-89% of all pancreatic adenocarcinomas, and the expression level of
117 drug target for the treatment of gastric and pancreatic adenocarcinoma, as evidenced by efforts to ta
118 une tumor microenvironment(TME), focusing on pancreatic adenocarcinoma because it is refractory to im
120 atients diagnosed as having T1 through T3 M0 pancreatic adenocarcinoma between January 1, 2004, and D
121 atients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma between January 1, 2006 and De
122 ents who underwent pancreatoduodenectomy for pancreatic adenocarcinoma between October 2001 and June
123 d that not only is MIF induced by hypoxia in pancreatic adenocarcinoma but MIF is also necessary for
124 ribed increased prevalence of these cells in pancreatic adenocarcinoma, but it remains unclear what m
125 s patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and
127 ngiography in the preoperative evaluation of pancreatic adenocarcinoma by using surgical findings as
128 non-small-cell lung carcinoma and another of pancreatic adenocarcinoma--by assessing responses to exi
129 ecialized setting, P-AR for locally advanced pancreatic adenocarcinoma can be performed safely with l
130 Our results suggest that HPR1 expressed in pancreatic adenocarcinomas can suppress the proliferatio
135 f either 250,000 cells of the transplantable pancreatic adenocarcinoma cell line Pan02 (cancer) or ph
138 se inhibitor, suppresses the growth of human pancreatic adenocarcinoma cell lines and that this growt
139 ucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is
143 ole for T1172 of L1 in regulating aspects of pancreatic adenocarcinoma cell phenotype and suggest the
144 d the anti-cancer effect of PSM and PSB over pancreatic adenocarcinoma cells and glioblastoma cells.
145 C4 with the receptor tyrosine kinase HER2 in pancreatic adenocarcinoma cells by reciprocal coimmunopr
146 st demonstrated that breast cancer cells and pancreatic adenocarcinoma cells generated micromolar lev
147 that COLXV significantly reduces invasion of pancreatic adenocarcinoma cells through a collagen I (CO
149 ble silencing of HMGA1 in MiaPaCa2 and PANC1 pancreatic adenocarcinoma cells was achieved by transfec
152 (CEA) is highly expressed on the surface of pancreatic adenocarcinoma cells; we investigated the eff
154 inding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic
155 tion was identified in 4.1% of patients with pancreatic adenocarcinoma compared with only 1.1% of can
156 minor alleles at R415Q had decreased risk of pancreatic adenocarcinoma compared with those who had tw
157 n homolog is up-regulated in the majority of pancreatic adenocarcinoma, completely prevents PDA devel
158 est that mutational inactivation of RNF43 in pancreatic adenocarcinoma confers Wnt dependency, and th
159 external patient cohort from a retrospective pancreatic adenocarcinoma database at Massachusetts Gene
160 The nomogram was created from a prospective pancreatic adenocarcinoma database that included 555 con
162 1 gene targets in small-cell lung cancer and pancreatic adenocarcinoma-derived cell lines compared wi
163 2 and May 2014, 137 patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based che
164 overall survival in patients with metastatic pancreatic adenocarcinoma for whom gemcitabine-based che
165 stromal fibroblasts adjacent to infiltrating pancreatic adenocarcinomas frequently express SPARC.
166 >/=18 years) with newly diagnosed metastatic pancreatic adenocarcinoma from the Comprehensive Cancer
167 ng patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to
172 ients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma have been prospectively follow
173 spirin and non-aspirin NSAID use and risk of pancreatic adenocarcinoma in 141,940 participants from t
177 nd adiposity duration and gain with incident pancreatic adenocarcinoma in the NIH-AARP Diet and Healt
179 rom 2004 to 2008 involving 973 patients with pancreatic adenocarcinoma (including 259 diabetic patien
180 n tumors than in adjacent normal tissues; in pancreatic adenocarcinoma, increased DUOX2 expression is
181 udy, we demonstrated that HPR1 expression in pancreatic adenocarcinomas inversely correlated with the
194 c K-RAS mutations are found in virtually all pancreatic adenocarcinomas, making the RAS pathway an id
196 verexpressed in several carcinomas including pancreatic adenocarcinoma, modulates cancer cell metabol
197 atic intraepithelial neoplasia (n = 80), and pancreatic adenocarcinoma (n = 67) showed a significant
198 elve out of 13 invasive malignancies (n = 12 pancreatic adenocarcinoma, n = 1 cholangiocarcinoma) wer
200 unique and reliable contrast agent targeting pancreatic adenocarcinoma, new multifunctional nanoparti
201 patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension
202 atabase was used to test the validity of the pancreatic adenocarcinoma nomogram established at Memori
204 Between 1994 and 2006, 184 incident cases of pancreatic adenocarcinoma occurred (follow-up to 11.7 ye
206 f 19 patients who had curative resection for pancreatic adenocarcinoma of the uncinate process were r
207 patients underwent resection for stage I-III pancreatic adenocarcinoma of which 23.2% had at least 1
209 f different tumor cells (COLO-357 metastatic pancreatic adenocarcinoma, OvCar3 ovarian carcinoma, MDA
210 ve cohort study, 1122 participants developed pancreatic adenocarcinoma over 4.2 million person-years.
212 h accurate staging and long-term survival in pancreatic adenocarcinoma (PaC) and to robustly determin
213 CHD5 expression in 80 patients with resected pancreatic adenocarcinoma (PAC) by immunohistochemical a
216 s detected in 73% of xenografts derived from pancreatic adenocarcinoma patients and 71% of pancreatic
217 dictive value of hENT1 levels in a cohort of pancreatic adenocarcinoma patients from the large prospe
218 Cancer Data Base was queried for T1-3N0-1M0 pancreatic adenocarcinoma patients who underwent PD.
220 described GIPC expression in different human pancreatic adenocarcinoma (PCA) cell lines and we examin
222 rowth-inhibitory action of a patient-derived pancreatic adenocarcinoma, PD002: paclitaxel (IC(50): 1.
226 cells (CPNI) is found in most patients with pancreatic adenocarcinomas (PDA), prostate, or head and
229 trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational c
230 motherapy enhanced drug uptake and effect in pancreatic adenocarcinoma (PDAC), notorious for having p
240 re being applied to primary cells from human pancreatic adenocarcinomas propagated in nude mice.
241 Forty-eight patients with locally advanced pancreatic adenocarcinoma received gemcitabine (30 mg/m2
243 ic adenocarcinoma), and HPAF-II cells (human pancreatic adenocarcinoma), respectively) with CFPAC-1 c
244 when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a
247 investigation of this promising approach in pancreatic adenocarcinoma.See related article by Zhang e
248 ysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identif
250 portantly, we observed downregulation of the pancreatic adenocarcinoma signaling pathway in MYB-silen
251 lly overexpressed in 16 of 17 (94%) clinical pancreatic adenocarcinoma specimens compared with the su
256 ppaB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of thi
257 o discern the regulatory role(s) of NRP-1 in pancreatic adenocarcinoma that lack these coreceptors, w
258 t inhibit tumor growth, and, specifically in pancreatic adenocarcinoma, the role of CCR5 in the homin
259 vel role for Reg3beta as a tumor promoter in pancreatic adenocarcinoma through the regulation of tumo
260 had little to offer patients with inoperable pancreatic adenocarcinoma; thus, many patients seek alte
261 ion was assessed immunohistochemically on 70 pancreatic adenocarcinoma tissue specimens and was stati
263 pproval rates varied from 0% (zero of 45) in pancreatic adenocarcinoma to 34.8% (24 of 69) for colon
264 ells inhibited secretion of a protein called pancreatic adenocarcinoma up-regulated factor (PAUF) but
266 f podocalyxin in migration and metastasis of pancreatic adenocarcinomas using SW1990 and Pa03c as cel
267 immunohistochemistry in a series of 99 human pancreatic adenocarcinomas versus 48 normal pancreatic t
270 sing oncogenic Kras-driven GEMMs of lung and pancreatic adenocarcinoma, we recently showed that these
273 Previously treated patients with metastatic pancreatic adenocarcinoma were randomly assigned at a ra
274 unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to rece
276 The records of 156 consecutive patients with pancreatic adenocarcinoma were retrospectively evaluated
277 Chemotherapy-naive patients with metastatic pancreatic adenocarcinoma were treated with a combinatio
278 ing a xenograft model in which primary human pancreatic adenocarcinomas were grown in immunocompromis
279 lood loss were lower after training and more pancreatic adenocarcinomas were resected (7 [10%] vs 28
280 Integrin alpha6beta4 is up-regulated in pancreatic adenocarcinomas where it contributes to carci
281 etastasis in an autochthonous mouse model of pancreatic adenocarcinoma-whereas conditional knockout o
282 aB is constitutively activated in most human pancreatic adenocarcinoma, which is a deadly malignancy
283 receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the dea
285 d in a significant proportion of gastric and pancreatic adenocarcinomas, while normal tissue expressi
286 n 4.1 states that all patients with resected pancreatic adenocarcinoma who did not receive preoperati
288 se To test the hypothesis that patients with pancreatic adenocarcinoma who otherwise are viewed to ha
289 reviewed to identify patients with invasive pancreatic adenocarcinoma who underwent pancreatectomy w
290 nes on overall survival of 378 patients with pancreatic adenocarcinoma who were treated at University
292 g in groups at high familial risk can detect pancreatic adenocarcinoma with limited evidence of minim
293 rane mucin, which is aberrantly expressed in pancreatic adenocarcinoma with no detectable expression
294 a biologic rationale to treat patients with pancreatic adenocarcinoma with the nontoxic phytochemica
295 could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for ear
300 omal elements into expanding patient-derived pancreatic adenocarcinoma xenografts, establishing the i